trimethoprim--sulfamethoxazole-drug-combination and Wiskott-Aldrich-Syndrome

Early bone marrow transplant is now standard treatment for infants with severe immunodeficiencies such as Wiskott-Aldrich Syndrome (WAS), but results in older children and adults are poor. Non-myeloablative transplant has shown promise in the treatment of older children, who are likely to have active infections and organ damage. We describe a non-myeloablative transplant of a 26-year-old man with WAS, undertaken because of severe infections and vasculitis. Partial engraftment and immunorestoration were achieved. The patient is well 1 year post transplantation.

Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cyclophosphamide; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Penicillin V; Transplantation Chimera; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Wiskott-Aldrich Syndrome